US Federal Securities Law Liability Insurance for Hong Kong Issuers: Coverage for Companies and Individuals

The number of Hong Kong-incorporated companies filing for US initial public offerings on the NYSE or Nasdaq reached 14 in the first nine months of 2025, a 40% increase year-on-year, according to filings data compiled by the US Listing Desk. This surge, driven by a stabilising interest rate environment and a rebound in technology-sector valuations, has brought renewed scrutiny to a specific cost centre often underestimated in pre-IPO budgeting: US federal securities law liability insurance. For Hong Kong issuers and their directors, the premium for Directors & Officers (D&O) liability coverage tailored to US federal securities claims has risen by an average of 22% since Q4 2024, according to broker estimates from Howden Specialty. The increase is not a market-wide phenomenon but a targeted recalibration by underwriters responding to the SEC’s aggressive enforcement posture under the 2024-2025 strategic plan, which prioritises issuer-side fraud and disclosure failures. For a Hong Kong company targeting a USD 50 million Nasdaq listing, the annual D&O premium now typically ranges between USD 400,000 and USD 700,000, depending on industry risk and corporate governance history. This article dissects the coverage structure, the specific exclusions relevant to Hong Kong issuers, and the underwriting factors that determine premium pricing.

The Coverage Structure: Distinguishing Entity Coverage from Individual Indemnification

US federal securities law liability insurance for Hong Kong issuers is not a single policy but a layered structure that must address the bifurcated legal exposure under the Securities Act of 1933 and the Securities Exchange Act of 1934. The primary policy, typically written by a London or Bermuda-based carrier, provides Side A coverage for individual directors and officers when the company cannot indemnify them—for example, under Hong Kong law restrictions in the Companies Ordinance (Cap. 622) or due to insolvency. Side B coverage reimburses the company when it has indemnified its directors, and Side C coverage protects the entity itself against securities claims.

For a Hong Kong issuer with a Cayman Islands holding company and a Hong Kong operating subsidiary, the policy must explicitly name each entity in the corporate structure. A common mistake is assuming a single entity policy covers the Hong Kong operating subsidiary; it does not, unless the subsidiary is listed as a “Named Entity” on the policy schedule. Underwriters at Lloyd’s, which writes approximately 35% of non-US D&O placements for Asian issuers, according to 2024 market share data from the International Underwriting Association, now require a full organisational chart as part of the underwriting submission. The chart must show the BVI intermediate holding company, the Hong Kong operating company, and any PRC subsidiaries, as the US securities laws’ extraterritorial reach under the Morrison v. National Australia Bank (2010) framework means that a claim can arise from conduct within the US that is “in connection with” the purchase or sale of a security, even if the issuer is domiciled in Hong Kong.

Side A: The Critical Protection for Individual Directors

Side A coverage is the most important component for Hong Kong directors, particularly those based in Hong Kong who may not be indemnifiable under the company’s bye-laws. Section 359 of the Companies Ordinance (Cap. 622) prohibits a company from indemnifying a director against liability arising from negligence, default, breach of duty, or breach of trust, unless the company has obtained a court order or the director has acted in good faith. This statutory restriction means that the Side A policy is the only reliable source of indemnification for a Hong Kong-resident director facing a US securities class action.

The premium for Side A-only coverage for a Hong Kong issuer is typically 60-70% of the total D&O premium, reflecting the higher risk for underwriters. For a typical Nasdaq-listed Hong Kong issuer with a market capitalisation of USD 200 million, the Side A premium component alone can range from USD 250,000 to USD 450,000 per annum, based on 2025 broker quotes compiled by Aon’s Hong Kong office. The limit of liability for Side A is usually set at USD 5 million to USD 10 million for the individual directors, with a separate aggregate limit for the entity coverage.

Side C: Entity Coverage and the Securities Act Section 11 Risk

Side C coverage, which protects the company itself, has become more expensive since the US Supreme Court’s 2023 decision in Slack Technologies, LLC v. Pirani, which affirmed that Section 11 of the Securities Act of 1933 imposes strict liability on issuers for material misstatements in registration statements, regardless of whether the plaintiff purchased shares in the IPO or in the secondary market. For a Hong Kong issuer conducting a firm-commitment underwriting on the Nasdaq, this decision expanded the potential plaintiff class, increasing the expected claim size. Underwriters have responded by raising Side C premiums by 15-20% for issuers with a PRC operating footprint, citing the additional complexity of verifying disclosures about VIE structures and PRC regulatory approvals.

Specific Exclusions and Endorsements for Hong Kong Issuers

Standard D&O policies contain exclusions that are particularly problematic for Hong Kong companies with PRC operations. The “Regulatory Exclusion” or “Securities and Exchange Commission (SEC) Investigation Exclusion” is the most common. This exclusion removes coverage for claims arising from or related to any SEC investigation, subpoena, or informal inquiry, unless the issuer has specifically purchased a “Regulatory Defence” endorsement. For a Hong Kong issuer that has received an SEC comment letter on its F-1 registration statement—a near-universal occurrence in 2025—the cost of responding to that letter is not covered under a standard policy. The endorsement adds approximately 10-15% to the premium, according to 2025 underwriting guidelines from Berkshire Hathaway Specialty Insurance.

The PRC VIE and National Security Exclusion

Since the SEC’s 2021 statement on variable interest entities (VIEs) and the subsequent PCAOB access law, underwriters have introduced a “PRC VIE and National Security Exclusion” into policies for Hong Kong issuers. This exclusion removes coverage for any claim arising from the invalidation, restructuring, or regulatory seizure of a VIE structure, or from any action by a PRC government authority that affects the issuer’s ability to operate. For a Hong Kong issuer with a VIE structure in the PRC, this exclusion is effectively a coverage gap for the most significant risk scenario. Insurers are willing to remove this exclusion only if the issuer provides a legal opinion from a PRC law firm confirming the validity of the VIE structure under current PRC regulations, and if the issuer’s prospectus contains a specific risk factor disclosure about the VIE structure. The 2025 SFC’s guidance on overseas listing structures (Circular to Licensed Corporations, 15 January 2025) explicitly notes that Hong Kong issuers must disclose the VIE structure in their listing documents and that the SFC will consider the adequacy of such disclosure when reviewing sponsor work.

Bribery and Corruption Exclusion: The Hong Kong ICAC Nexus

Another critical exclusion is the “Bribery and Corruption Exclusion,” which removes coverage for claims arising from violations of the US Foreign Corrupt Practices Act (FCPA) or any equivalent Hong Kong law, including the Prevention of Bribery Ordinance (Cap. 201). For a Hong Kong issuer with government contracts in the PRC or Southeast Asia, this exclusion is particularly relevant. The Hong Kong Independent Commission Against Corruption (ICAC) has jurisdiction over bribery offences committed in Hong Kong, and a US securities class action could arise if a Hong Kong issuer fails to disclose an ICAC investigation in its SEC filings. Underwriters now require issuers to complete a detailed FCPA/anti-bribery questionnaire as part of the application, and any “yes” answer to questions about government contract payments triggers a mandatory 48-hour underwriting hold and potential premium loading of 20-30%.

Underwriting Factors and Premium Determinants in 2025

The underwriting process for a Hong Kong issuer’s US D&O policy has become more rigorous since the 2024 collapse of several SPAC-merged Hong Kong companies, which resulted in aggregate claims of USD 1.2 billion, according to data from the Stanford Securities Class Action Clearinghouse. Underwriters now apply a “Hong Kong issuer scorecard” that weights five factors: corporate governance history, auditor quality, PRC exposure, industry sector, and the strength of the issuer’s Hong Kong legal counsel.

Corporate Governance History and the SFC’s Enforcement Record

The SFC’s 2024 annual report recorded 47 enforcement actions against listed companies and their directors, a 12% increase from 2023. Underwriters review the SFC’s public enforcement database and will decline coverage or apply a 50% premium surcharge for any issuer whose directors have been subject to an SFC investigation or disciplinary action within the past five years. For a Hong Kong issuer with a clean record, the premium loading for the “governance risk” factor is typically 0-10%; for an issuer with one prior SFC action, the loading jumps to 25-40%.

Auditor Quality and PCAOB Registration

Since the PCAOB’s 2022-2024 inspection cycle, which found deficiencies in 60% of PRC-based audit firms inspected, underwriters have required that the issuer’s auditor be a PCAOB-registered firm with no outstanding critical inspection findings. For a Hong Kong issuer using a Big Four auditor (Deloitte, EY, KPMG, PwC), the premium reduction is approximately 10-15% compared to an issuer using a smaller Hong Kong-based firm. The 2025 HKEX consultation paper on auditor rotation (Consultation Paper on Proposed Amendments to the Listing Rules Relating to Auditor Rotation, March 2025) proposes mandatory rotation every 10 years for Main Board issuers, which will further affect underwriters’ risk assessment.

Industry Sector and the Technology Premium

Technology and life sciences issuers from Hong Kong face the highest premiums, reflecting the sector’s volatility and the complexity of revenue recognition disclosures. For a Hong Kong biotech issuer listing on the Nasdaq under the HKEX Chapter 18A framework (which permits pre-revenue biotech listings), the D&O premium is typically 30-50% higher than for a traditional manufacturing company. Underwriters cite the 2024 SEC enforcement action against a Hong Kong biotech issuer that misstated its clinical trial results as the basis for this loading. The premium for a USD 100 million market cap Hong Kong biotech is now approximately USD 600,000 to USD 900,000 per annum, compared to USD 350,000 to USD 500,000 for a similarly sized industrial issuer.

Actionable Takeaways for Hong Kong Issuers and Their Advisors

1. Initiate the D&O insurance placement at least 12 weeks before the expected Nasdaq or NYSE listing date, as the underwriting process now requires a full organisational chart, a PRC legal opinion on VIE validity, and an SFC enforcement history check, all of which can take 4-6 weeks to compile.
2. Negotiate the removal of the PRC VIE and National Security Exclusion by providing a contemporaneous legal opinion from a PRC law firm and ensuring the prospectus contains a dedicated risk factor on VIE structure validity, as this exclusion represents the single largest coverage gap for Hong Kong issuers with PRC operations.
3. Purchase the Regulatory Defence endorsement to cover the cost of responding to SEC comment letters and informal inquiries, as the standard policy’s Regulatory Exclusion will otherwise leave the issuer bearing 100% of these costs, which can exceed USD 200,000 for a complex F-1 review.
4. Ensure Side A coverage limits are set at a minimum of USD 5 million per director, and confirm that the policy explicitly covers directors resident in Hong Kong under the Companies Ordinance (Cap. 622) restrictions, as the statutory prohibition on corporate indemnification makes Side A the only reliable protection.
5. Engage a Hong Kong-based insurance broker with dedicated US D&O expertise, as the 2025 market requires knowledge of both Hong Kong corporate law and US securities law liability, and a broker without this dual expertise may miss critical exclusions or endorsements that could void coverage in a claim scenario.